Browsing Tag
Enhanze
2 posts
Halozyme Therapeutics (HALO) completes $900m Elektrofi deal—what’s next for its royalty roadmap?
Halozyme finalizes $900M Elektrofi deal to strengthen its subcutaneous biologics platform. Discover how this move impacts future royalties and delivery formats.
Why Halozyme Therapeutics is raising $1.3bn in convertible notes and what it means for HALO stock
Halozyme Therapeutics raises $1.3B via convertible notes to refinance debt and fund growth. Find out what this means for biotech investors and royalty markets.